S3-6 Problems and Meanings of Genome-based Drug Discovery in Japanese Pharmaceutical Companies(SYMPOSIUM 3: BENEFITS OF PHARMACOGENOMICS/PHARMACOGENETICS IN PHARMACEUTICAL DEVELOPMENT)(Proceedings of the 31st Annual Meeting)
スポンサーリンク
概要
- 論文の詳細を見る
- 日本トキシコロジー学会の論文
- 2004-10-29
著者
-
SAGAMI Fumio
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
Sagami Fumio
第一三共安全性研究所
-
Sagami Fumio
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Sagami Fumio
Drug Safety Research Laboratories Eisai Co. Ltd.
-
Sagami Fumio
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Sagami Fumio
Department Of Drug Safety Research Eisai Kawashima Research Laboratories Eisai Co. Ltd.
-
Ohkura Takako
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Mutai Mamoru
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
KOTOSAI Kounori
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
KAWAHARA Jun-ichi
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
INOUE Akiharu
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
OHKURA Takako
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
KOHIRA Terutomo
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
NAGAKI Yasuhiro
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
NEMOTO Shingo
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
MATSUMOTO Shinichi
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
NAITO Shinsaku
Non-Clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
Kawahara Jun-ichi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Inoue Akiharu
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Nemoto Shingo
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Naito Shinsaku
Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee Non-clinical Evaluation Sub
-
Kohira Terutomo
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Nagaki Yasuhiro
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Kotosai Kounori
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Naito Shinsaku
Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee Non-clinical Evaluation Sub
-
Matsumoto Shinichi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Naito Shinsaku
Non-clinical Evaluation Expert Committee Drug Evaluation Committee Japan Pharmaceutical Manufacturers Association (jpma)
-
OHKURA Takako
Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association
関連論文
- The predictivity of preliminary embryo-fetal development (EFD) studies : results of a retrospective survey in Japanese pharmaceutical companies
- Collaborative work on evaluation of ovarian toxicity by repeated-dose and fertility studies in female rats
- Safety assessment of biopharmaceuticals : Japanese perspective on ICH S6 guideline maintenance
- Points to consider on the non-clinical safety evaluation of anticancer drugs
- CURRENT OPINION : SAFETY EVALUATION OF DRUG METABOLITES IN DEVELOPMENT OF PHARMACEUTICALS
- "POINTS TO CONSIDER" REGARDING SAFETY ASSESSMENT OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS IN NON-CLINICAL STUDIES (ENGLISH TRANSLATION)
- Current status of pharmaceutical industries in Japan on pharmacogenomics and toxicogenomics in 2005(Toxicogenomics, Toxicoproteomics, Proceedings of the 32nd Annual Meeting)
- S3-6 Problems and Meanings of Genome-based Drug Discovery in Japanese Pharmaceutical Companies(SYMPOSIUM 3: BENEFITS OF PHARMACOGENOMICS/PHARMACOGENETICS IN PHARMACEUTICAL DEVELOPMENT)(Proceedings of the 31st Annual Meeting)
- P8-49 Questionnaire Survey of GLP Operation for S7A Safety Pharmacology Study in Japanese and Foreign CROs(BLOOD/TOXICOKINETICS/OTHERS-2)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-09 No-Observed Adverse Effect Level(NOAEL) : Judging Criteria and Purpose in Safety Assessment of Pharmaceuticals(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-08 Questionnaire Survey on No Observed Adverse Effect Level(2) : Regulatory Comments and Company(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-07 Questionnaire Survey on No Observed Adverse Effect Level(1) : Concept of NOAEL(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Survey of pharmacology study conduct using outside sources in pharmaceutical companies in Japan.(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURVEY))
- Study Monitor : The Surveillance of Outsourced Non-Clinical Studies : Draft Report, Final Report, Archives, and Quality Assurance(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CUR
- Study monitor : the Surveillance of Outsourced Non-Clinical Studies (Reproductive Studies,Pathology and Toxicokinetics).(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURV
- Study Monitor. The Surveillance of Outsourced Non-Clinical Studies : Testing facility checking, Protocol, Formulation and In-life phase(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STU
- Study Monitor. Introduction of the Surveillance for Outsourcing Non-Clinical Studies and Summary of Toxicology.(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURVEY))
- P7-39 Current Analysis and Prospects of New Toxicological Biomarker : Biomarkers of Hepatotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- P7-38 Current analysis and prospects of new toxicological biomarker : biomarkers of cardiotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- P7-37 Current Analysis and Prospects of New Toxicological Biomarker : Biomarkers of Nephrotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- S13-1 Current analysis and prospects of new toxicological biomarkers : with central focus on heart, liver and kidney(SYMPOSIUM 13: CURRENT STATUS AND FUTURE ASPECTS OF NEW TOXICOLOGICALLY RESPONSIBLE BIOMARKERS)(Proceedings of the 31st Annual Meeting)
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 3. LOW MOLECULAR WEIGHT ELICITOGENIC ANTIGENS OF IODINE ALLERGY
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 2. IODINATED PROTEIN ANTIGENS AND THEIR GENERATION FROM INORGANIC AND ORGANIC IODINE-CONTAINING CHEMICALS
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 1. ANTIGEN RECOGNITION OF GUINEA PIG ANTI-IODINE ANTIBODY
- P-11 Application of hepatocytes cultured in a sandwich configuration to toxicity assessment.(Proceedings of the 27th Annual Meeting)
- Mechanism for benzothiazole derivative-induced hepatotoxicity in rats(SYMPOSIUM 1 : MECHANISMS OF HEPATOTOXIC EFFECTS)
- P-90 Collaborative Work to Evaluate Toxicity on Male Reproductive Organs with 2 Weeks Repeated Daily Dosing in Rats : Testicular Toxicity of E7010, A Sulfonamide Tubulin Polymerlzation Inhibitor(Proceedings of the 27th Annual Meeting)
- COLLABORATIVE WORK TO EVALUATE TOXICITY ON MALE REPRODUCTIVE ORGANS BY REPEATED DOSE STUDIES IN RATS : 17)TESTICULAR TOXICITY OF E7010, A SULFONAMIDE TUBULIN POLYMERIZATION INHIBITOR
- TOXICOLOGICAL RESPONSE OF RATS TO A NOVEL MONOAMINE OXIDASE TYPE-A INHIBITOR, (5R)-3-[2-((1S)-3-CYANO-1-HYDROX-YPROPYL)BENZOTHIAZOL-6-YL]-5-METHOXYMETHYL-2-OXAZOLIDI-NONE (E2011), ORALLY ADMINISTERED FOR 13 WEEKS
- "B-5 Modification of Drug Conjugation Pathway by Repeated Administration of Conjugating Enzyme Inhibitors in Rats.
- 21C-02-4 Hepatic Drug Metabolizing Enzymes in CB6F1-TgrasH2 Mice.
- TOXICOKINETICS:ITS SIGNIFICANCE AND PRACTICAL PROBLEMS
- DETERMINATION OF THE TIME AT WHICH CONGENITAL HYDROCEPHALUS IS INDUCED WITH HIGHER INCIDENCE DURING THE EARLY GESTATIONAL PERIOD IN RATS
- Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop
- Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions : correlation analysis of 142 approved drugs in Japan